Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Olema Pharmaceuticals (NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on targeted breast cancer therapies, has granted stock options to 11 new employees. The inducement grants, approved under Nasdaq Rule 5635(c)(4), total 322,000 shares with an exercise price of $4.38 per share. The options vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over three years. These 10-year term options were granted under Olema's 2022 Inducement Plan as part of the company's employee compensation strategy.

Positive

• Company is expanding its workforce with 11 new hires, indicating business growth
• Stock options align employee interests with shareholders through long-term vesting schedule

Negative

• Potential dilution to existing shareholders from 322,000 new stock options

SAN FRANCISCO, June 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 11 new employees to purchase an aggregate of 322,000 shares of the Company's common stock, effective as of June 2, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $4.38 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on June 2, 2025. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.

Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical trial. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

How many stock options did Olema Pharmaceuticals (OLMA) grant to new employees in June 2025?

Olema granted stock options for 322,000 shares to 11 new employees, effective June 2, 2025.

What is the exercise price for OLMA's June 2025 employee stock options?

The exercise price is $4.38 per share, equal to the last reported sale price on Nasdaq on June 2, 2025.

What is the vesting schedule for Olema's June 2025 employee stock options?

The options vest over 4 years, with 25% vesting after the first year and the remainder vesting in 36 equal monthly installments over the following three years.

How long is the term of OLMA's June 2025 employee stock options?

The stock options have a 10-year term.

What is Nasdaq Listing Rule 5635(c)(4) under which OLMA granted these options?

This rule allows companies to grant equity as an inducement material to new employees entering into employment without shareholder approval.